Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 3Phase 1/2 2Phase 2 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Small Cell Lung Carcinoma 3Neoplasms 2Neoplasm Metastasis 1

Interventions

Etoposide 34Carboplatin 31Topotecan 24Cisplatin 21atezolizumab 11PM 01183 8durvalumab 7Irinotecan 7amrubicin 5PE regimen 4AMG 757 4rovalpituzumab tesirine 3pembrolizumab 3Magnetic Resonance Spectroscopy 3Dexamethasone 3tremelimumab 2tislelizumab 2etoposide phosphate 2apatinib 2Vitamin E 2Tiragolumab 2Specimen Handling 2Radiosurgery 2RRx-001 2Paclitaxel 2Memantine 2Injections 2EC regimen 2trilaciclib 1toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Small Cell Lung Carcinoma × rovalpituzumab tesirine × Clear all
NCT03033511 2021-07-29

MERU

AbbVie

Phase 3 Terminated
748 enrolled 13 charts
Thoracic

Neoplasms, Small Cell Lung Carcinoma

NCT03061812 2021-02-23

TAHOE

AbbVie

Phase 3 Completed
444 enrolled 16 charts
Thoracic

Neoplasm Metastasis, Small Cell Lung Carcinoma

NCT03334487 2018-12-26

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

AbbVie

Phase 3 Withdrawn
Thoracic

Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡